According to IMARC Group, the global Coronary Stents Market Size reached USD 12.3 Billion in 2025 and is projected to reach USD 19.3 Billion by 2034, expanding at a CAGR of 4.98% during 2026–2034. This consistent Coronary Stents Market Growth is being driven by the rising global burden of cardiovascular disease, an aging population more prone to arterial narrowing, continued innovation in stent materials and delivery mechanisms, and expanding healthcare investment across emerging economies.

Coronary Stents Industry Overview

A coronary stent is a small, tubular medical device implanted within a narrowed or blocked coronary artery to keep the vessel open and restore adequate blood flow to the heart muscle. Most modern stents are coated with a therapeutic agent that is released gradually to limit the tissue overgrowth that can cause the artery to re-narrow, a process known as restenosis. By preventing this re-narrowing, stents help relieve symptoms such as chest pain and breathlessness while lowering the likelihood of repeat procedures.

Coronary stenting procedures are used across a range of clinical scenarios:

• Chronic coronary artery disease: Restoring blood flow in patients with progressively narrowed arteries due to plaque buildup
• Acute coronary events: Emergency stenting following heart attacks to quickly reopen blocked vessels
• Complex and high-risk lesions: Use of specialized bioresorbable and drug-coated platforms for calcified or bifurcated arterial segments
• Elderly and comorbid patient populations: Self-expanding and customizable stent designs suited to fragile or irregular vessel anatomy
• Minimally invasive cardiac care: Growing preference for catheter-based stenting over open-heart bypass surgery given shorter recovery times

Global Coronary Stents Market Size & Key Statistics

The table below summarizes the key statistics from IMARC Group's coronary stents market research:

Request for a Sample Report for Detailed Coronary Stents Market Share Evaluation: https://www.imarcgroup.com/coronary-stents-market/requestsample

Key Market Drivers & Coronary Stents Market Trends in 2026

Several factors are shaping current Coronary Stents Market Trends and supporting sustained expansion across global cardiovascular care markets:

1. Growing Preference for Drug-Eluting Stents (DES)

Drug-eluting stents continue to gain favor over bare-metal alternatives because their medicated coatings substantially reduce restenosis rates and the need for repeat interventions. In May 2024, Abbott introduced its XIENCE Sierra everolimus-eluting stent system in India, featuring an updated delivery system and expanded sizing to address complex lesions, reinforcing DES adoption as a core coronary stents market driver.

2. Advancing Stent Materials and Delivery Technology

Innovation in bioresorbable stents, which dissolve after completing their therapeutic role, is reducing risks associated with permanent implants such as late-stage thrombosis. MicroPort Scientific's Firesorb bioresorbable stent received regulatory approval in China in July 2024 on the strength of favorable clinical outcomes, while drug-coated balloons are emerging as a complementary, device-free option for high-risk restenosis cases.

3. Expanding Elderly Population and Rising Cardiovascular Disease Burden

As the global population ages, arteries naturally stiffen and narrow, increasing susceptibility to coronary artery disease. The World Health Organization projects that roughly one in six people will be over 60 by 2030, rising to 2.1 billion people aged 60 and above by 2050. This demographic shift is steadily lifting demand for coronary interventions worldwide.

4. Rising Demand for Patient-Centric, Minimally Invasive Solutions

Patients increasingly favor treatments that minimize recovery time and preserve quality of life, a standard that catheter-based stenting meets more effectively than open surgical alternatives. Elixir Medical's DynamX Bioadaptor demonstrated a target lesion failure rate of just 2.35% in the 2024 INFINITY-SWEDEHEART trial, closely matching established drug-eluting benchmarks and illustrating how patient-centered design is reshaping treatment choices.

5. Expanding Healthcare Infrastructure Investment

Public and private capital continues to flow into hospital modernization, particularly across developing regions, widening access to advanced cardiac interventions. Tata Group's 2025 investment of roughly INR 500 crore in upgrading Mumbai's Breach Candy Hospital illustrates how infrastructure spending is extending coronary stent access to a broader patient base.

6. Strategic Partnerships Across the Value Chain

Collaboration between device manufacturers, research institutions, and healthcare providers is accelerating innovation while broadening distribution into underserved regions. Such partnerships are helping streamline manufacturing, lower costs, and integrate next-generation technologies, further reinforcing coronary stents market growth.

Key Market Segmentation

By Type

Drug-Eluting Stents — Largest Segment: Drug-eluting stents lead the type segmentation owing to their medicated coatings, which slowly release compounds that inhibit excess tissue growth and lower restenosis risk. This translates into more durable outcomes for patients with coronary artery disease and continues to anchor demand across hospital cardiac catheterization labs.

Bare-Metal Coronary Stents: These uncoated stents remain a lower-cost option in select cases, though adoption continues to decline as drug-eluting platforms demonstrate superior long-term performance.

Bioabsorbable Stents: This emerging category, designed to dissolve after supporting arterial healing, is gaining traction as clinical evidence around long-term safety and efficacy continues to build.

By Biomaterial

Metallic Biomaterial — Largest Segment: Metallic biomaterials dominate due to their strength, durability, and proven biocompatibility, offering the structural stability required for consistent long-term performance inside the coronary vasculature.

Polymeric Biomaterial: Polymeric platforms, often used in bioresorbable designs, are expanding as manufacturers pursue devices that support natural vessel healing without a permanent metallic implant.

Natural Biomaterial: A smaller but developing category exploring biologically derived materials for enhanced compatibility and reduced inflammatory response.

By Mode of Delivery

Self-Expanding Stents — Largest Segment: Self-expanding designs hold the largest share of Coronary Stents Market Share within this segmentation because they automatically conform to vessel dimensions, simplifying placement and improving procedural consistency.

Balloon-Expandable Stents: These remain widely used for precise, operator-controlled deployment, particularly in calcified or heavily diseased arterial segments.

By End User

Hospitals — Largest Segment: Hospitals account for the dominant end-use share, supported by advanced catheterization infrastructure, specialized cardiac care teams, and round-the-clock capacity to manage complex or emergency procedures.

Ambulatory Surgical Centers: These centers are gradually expanding their role in lower-risk elective stenting procedures, supported by shorter recovery protocols and cost efficiencies.

Others: Includes specialty cardiac clinics and research institutions supporting diagnostic and interventional cardiology work.

Regional Coronary Stents Market Analysis

North America leads the global coronary stents market, underpinned by advanced healthcare systems, early adoption of emerging stent technologies, and a robust regulatory environment that supports continuous product innovation.

Asia-Pacific is positioned for sustained expansion, driven by rising healthcare spending, a growing base of patients with cardiovascular disease, and increasing local manufacturing of interventional cardiology devices across China, India, and other developing markets.

Connect for Detailed Coronary Stents Market Share Segmentation Analysis — Speak to an Analyst: https://www.imarcgroup.com/request?type=report&id=6083&flag=C

Leading Players in the Global Coronary Stents Industry

The global coronary stents market includes a mix of established multinational device makers and specialized interventional cardiology manufacturers. Companies profiled in the IMARC Group report include:

• Abbott Laboratories
• B. Braun Melsungen AG
• Biotronik SE & Co. KG
• Boston Scientific Corporation
• Elixir Medical Corporation
• Lepu Medical Technology (Beijing) Co. Ltd.
• Medtronic plc
• Meril Life Sciences Pvt. Ltd.
• MicroPort Scientific Corporation
• Terumo Corporation
• Translumina GmbH

This represents a partial list; the complete competitive profiling is available in the full IMARC Group report.

Latest Coronary Stents Market Industry Developments

May 2025 — SGPGI Lucknow

The institute introduced AI-enabled intravascular optical coherence tomography (OCT) imaging to improve the precision of angioplasty procedures, offering high-resolution, real-time visualization of arterial plaque to support more accurate stent placement, particularly among younger patients in India.

February 2025 — Teleflex

Teleflex agreed to acquire Biotronik's vascular intervention portfolio — including coronary stents, drug-coated balloons, and the PK Papyrus rescue stent — in a deal valued at roughly €760 million, expanding its coronary and peripheral device offerings.

March 2024 — Boston Scientific

The company received FDA approval for its AGENT drug-coated balloon, the first such device approved in the United States for treating in-stent restenosis, backed by strong supporting trial data.

December 2023 — Terumo India

Terumo launched the Ultimaster Nagomi drug-eluting stent in India, designed to accommodate both small and large coronary arteries and offer more customized treatment options across a broader patient population.

August 2024 — Sahajanand Medical Technologies

Global private equity firms including KKR, Apax Partners, and TPG Capital moved to acquire Sahajanand Medical Technologies, India's largest cardiac stent manufacturer, in a deal valuing the company at roughly INR 3,500–4,000 crore.

About Us

IMARC Group is a leading global market research company providing data-driven insights and expert consulting services to businesses seeking to achieve their strategic objectives. With a multi-disciplinary team of industry experts, IMARC delivers thorough, reliable market intelligence across sectors including Healthcare, Technology, Chemicals, Energy, Food & Beverages, and more.

Contact Us

IMARC Group

United States: +1-201-971-6302

India: +91-120-433-0800

United Kingdom: +44-753-714-6104